出血性脑卒中产品

Search documents
微创脑科学(02172.HK)中期收入3.83亿元 同比下降6.2%
Ge Long Hui· 2025-08-27 14:03
Core Viewpoint - MicroPort NeuroTech (02172.HK) reported a revenue of RMB 382.9 million for the six months ending June 30, 2025, a decrease of 6.2% compared to RMB 408.2 million for the same period in 2024, primarily due to various factors affecting product sales and market dynamics [1] Revenue Breakdown - The revenue is mainly derived from hemorrhagic stroke products, carotid artery atherosclerosis products, and acute ischemic stroke products [1] - The overseas business continued to show strong growth, with revenue increasing approximately 67.4% year-on-year, and sales in the Asia-Pacific, North America, Latin America, and Europe, Middle East, and Africa regions all experienced varying degrees of rapid growth [1] - Revenue from hemorrhagic stroke products, including the spring coil series and the globally unique WILLIS intracranial covered stent, maintained rapid growth, while the market share of spring coils increased [1] - Revenue from carotid artery atherosclerosis products declined mainly due to the cessation of cooperation with original agents and the impact of centralized procurement in certain regions [1] Profitability Metrics - The company's gross profit margin was 73.4%, an increase of 1.1 percentage points from 72.3% in the same period last year, attributed to improved production efficiency [1] - The net profit recorded during the reporting period was approximately RMB 92.7 million [1] Dividend Announcement - The board of directors proposed an interim dividend of HKD 0.05 per ordinary share for the six months ending June 30, 2025 [1]
7.62亿!微创脑科学最新年报
思宇MedTech· 2025-04-02 10:06
报名:首届全球眼科大会 | 议程更新 报名:首届全球心血管大会 | 奖项申报 报名:首届全球骨科大会 | 奖项评选 合作伙伴征集:2025全球手术机器人大会 2025年3月27日,微创脑科学发布2024年年报。 # 财 报数据 # 关 于微创 脑 科 学 公司 2024 年实现收入 7.62 亿元,同比增长 14.4% 。经计算,公司 24 年 H2 实现收入 3.53 亿元,同比 下滑 3.6% 。 2024 年,公司实现归母净利润 2.54 亿元,同比增长 74.6% ,主要得益于收入的增长及运营效率的提升。公司 经调整净利润为 2.82 亿元,同比增长 44.2% 。经计算,公司 24 年 H2 实现归母净利润 1.11 亿元,同比增长 35.8% 。 分产品来看: 24 年出血性脑卒中产品实现营收 4.02 亿元,同比下滑 5.5% ;脑动脉狭窄类产品实现营收 2.68 亿元,同比增长 74.6% ;急性缺血性产品实现收入 0.47 亿元,同比增长 82.0% ;通路产品实现收入 0.43 亿 元,同比下滑 26.7% 。 # 公 司经营 亮 点 分地区来看 , 24 年国内收入 6.86 亿,同比增 ...